A recent study published in JAMA Cardiology suggests the price tag on Pfizer’s Vyndaqel is too high.
According to a FiercePharma article, the heart medication received FDA approval in 2019, and hit the market with a $225,000 per year price tag.
“Unfortunately, the high copays required by the Medicare Part D benefit design often result in seniors having to forgo their needed prescriptions,” Pfizer told FiercePharma in a statement. “This is unfair.”
To read the full report by FiercePharma, click here.
Click here to read the study in JAMA Cardiology. (Paid subscription required)